V. V. Palm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
V. V. Palm has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dmitriy A. Reshchikov
Russian Children’s Clinical Hospital – branch of the Pirogov Russian National Research Medical University
1 shared publication - Ekaterina Yu. Zakharova
Research Centre for Medical Genetics, 115522 Moscow, Russia
1 shared publication - Elena Efimovna Petryaykina
Pirogov Russian National Research Medical University
1 shared publication - Roni Mai
Department of Pediatric Surgery, Moscow Regional Scientific Research Clinical Institute M.F. Vladimirsky, Moscow, Russia; Department of Pediatric Neurosurgery, Russian Children's Clinical Hospital, Pirogov Russian National Research Medical University, Moscow, Russia
1 shared publication - Sergey Gorelikov
Russian Children’s Clinical Hospital – branch of the Pirogov Russian National Research Medical University
1 shared publication - Svetlana V. Mikhaylovna
Russian Children’s Clinical Hospital – branch of the Pirogov Russian National Research Medical University; Pirogov Russian National Research Medical University
1 shared publication
Latest Publications
- Open Access
- 6 March 2026
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 15 (4) , 10-16
Frameless stereotactic infusion of gene therapy into the putamen for AADC deficiency in children: technical and organizational aspects of implementation in Russia
Aim. To present the authors’ experience in implementing a frameless stereotactic infusion technique of a gene preparation using an adeno-associated vectored virus into the subcortical structures of the brain in children with aromatic L-amino acid decarboxylase deficiency (AADCd), with an emphasis on technical and organizational aspects. Materials and methods. From November 2024 to December 2025, six bilateral infusions of eladocagen exuparvovec (Upstaza®) were administered into the putamen of children with genetically confirmed AADCd in the Department of Pediatric Neurosurgery of the Russian Children’s Clinical Hospital. The key stages of patient selection, regulatory support, preoperative planning based on brain magnetic resonance imaging data, features of frameless navigation, the Z-shaped convection-enhanced infusion technique, and measures for preventing intra- and postoperative complications are described. The analysis of clinical outcomes is deliberately not presented in this work and is planned for a separate publication after increasing the sample size and follow-up observation. Results. In all 6 cases, accurate drug delivery to the putamen was ensured in accordance with preoperative planning, and no intraoperative complications were observed. Early postoperative magnetic resonance imaging monitoring revealed no clinically significant hemorrhagic or ischemic brain damage. In all cases, improvements in motor and autonomic symptoms of varying severity were noted during the first months of follow-up. Conclusion. The presented experience demonstrates the technical feasibility and safety of frameless stereotactic gene therapy for AADCd in children in a Federal Center setting. The proposed method can serve as the basis for a national treatment protocol for AADCd and the establishment of a reference center for gene therapy for central nervous system diseases.
- 6 March 2026
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 15 (4) , 10-16
Open AccessFrameless stereotactic infusion of gene therapy into the putamen for AADC deficiency in children: technical and organizational aspects of implementation in Russia
Aim. To present the authors’ experience in implementing a frameless stereotactic infusion technique of a gene preparation using an adeno-associated vectored virus into the subcortical structures of the brain in children with aromatic L-amino acid decarboxylase deficiency (AADCd), with an emphasis on technical and organizational aspects. Materials and methods. From November 2024 to December 2025, six bilateral infusions of eladocagen exuparvovec (Upstaza®) were administered into the putamen of children with genetically confirmed AADCd in the Department of Pediatric Neurosurgery of the Russian Children’s Clinical Hospital. The key stages of patient selection, regulatory support, preoperative planning based on brain magnetic resonance imaging data, features of frameless navigation, the Z-shaped convection-enhanced infusion technique, and measures for preventing intra- and postoperative complications are described. The analysis of clinical outcomes is deliberately not presented in this work and is planned for a separate publication after increasing the sample size and follow-up observation. Results. In all 6 cases, accurate drug delivery to the putamen was ensured in accordance with preoperative planning, and no intraoperative complications were observed. Early postoperative magnetic resonance imaging monitoring revealed no clinically significant hemorrhagic or ischemic brain damage. In all cases, improvements in motor and autonomic symptoms of varying severity were noted during the first months of follow-up. Conclusion. The presented experience demonstrates the technical feasibility and safety of frameless stereotactic gene therapy for AADCd in children in a Federal Center setting. The proposed method can serve as the basis for a national treatment protocol for AADCd and the establishment of a reference center for gene therapy for central nervous system diseases.